Last reviewed · How we verify
Antivert (meclozine)
At a glance
| Generic name | meclozine |
|---|---|
| Sponsor | Citron Pharma Llc |
| Drug class | Antiemetic |
| Target | Nuclear receptor subfamily 1 group I member 3 |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
- Motion sickness
- Prevention of Motion Sickness
- Vertigo
Common side effects
Key clinical trials
- Motion Sickness Medications and Vestibular Time Constant (PHASE4)
- Meclizine for Hepatocellular Carcinoma (PHASE1)
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance (PHASE2)
- Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin (PHASE3)
- Evaluation of Meclizine Orodispersible Tablet Pharmacokinetic in Human Volunteers (PHASE1,PHASE2)
- Meclizine Plasma Levels in Responders and Non-responders (PHASE4)
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (NA)
- Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antivert CI brief — competitive landscape report
- Antivert updates RSS · CI watch RSS
- Citron Pharma Llc portfolio CI